Long-acting insulin analogs such as insulin glargine will consistently remain at a relatively low level for a rather long period; therefore, interference of endogenous insulin makes sense in clamp studies conducted in patients with type 2 diabetes or the healthy people. This evidence concerns the gene INS and type 2 diabetes mellitus.